MedX Health Corp. Announces CE Mark for Its MOLEMATE(TM)/SIMSYS(TM) Skin Cancer Imaging Systems

MISSISSAUGA, ONTARIO--(Marketwired - Feb. 12, 2014) - MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE:MDX), a leader in skin cancer imaging and diagnostics, announced receipt of a CE Mark from Conformite Europeenne, which allows the Company to market its MoleMate and SIMSYS systems in Europe to dermatologists and to expand further its pharmacy-based sales channel.

"Adding CE approval to our existing Health Canada and FDA approvals is a very positive development" noted Rob von der Porten, President and CEO. "This allows us to expand our sales effort into all countries in the European Union. While skin cancer is the one of the most curable cancers if caught early, statistics indicate that it is one of the least screened-for cancers; our technology can be rolled-out to many health related facilities, including community health centers, clinics and pharmacies, thereby facilitating early screening which could save lives, but also reduce the number of unnecessary biopsies, two outcomes which would cut the burgeoning costs of health care as well as reduce patient anxiety and suffering."

"Over the past years, [MoleMate/SIMSYS] has been a great tool at reassuring patients that a lesion was benign if my exam alone was not enough to comfort them," says Dr. R.H. Falcon, Dermatologist, New York, NY. "Surprisingly in a few patients that I was worried clinically had Melanoma, who for whatever reason did not want a biopsy, I have been able to show them on the device the signs of the cancerous lesions and convince them to let me remove it. I can honestly say in the years since I have the device, I have been able to save some lives by convincing a patient they needed a lesion removed and were only convinced once they saw the image on the screen."

Leading European Dermatologist, Giuseppe Argenziano, M.D. recently conducted an internal study to evaluate the efficacy and accuracy of the MedX SIAscopy technology and device, notes "The MedX MoleMate system is an advanced screening device used in the early detection of skin cancer (melanoma) and precancerous skin lesions. The results of this study have been submitted and accepted for publication soon to be released in the Skin Research and Technology Journal." Dr. Argenziano is a leading expert in Dermatascopy skin evaluation techniques and has been following the development of the SIAscopy technology over the past 8 years.

Among the sophisticated equipment used by University of California Irvine Melanoma Center, physicians are currently using SIMSYS-MoleMate, "one of the most advanced melanoma imaging systems in the world. For patients with many moles, this computer imaging can make a big difference, it decreases the number of biopsies needed, so they won't look like a pincushion," explained Dr. James G. Jakowatz, surgical oncologist and UC Irvine Melanoma Center director, Dr. Janellen Smith, UC Irvine dermatologist and co-director of the Pigmented Lesion Program, UC Irvine.

About MedX Health Corp.

MedX is an ISO 13485 medical device manufacturing company, headquartered in Mississauga, Ontario, and is a global leader in skin cancer imaging and diagnostic devices and quality low level laser and light therapy technologies. MoleMate and SIMSYS skin cancer imaging and diagnostic systems offer significant advancement in the early detection of potentially life threatening moles and lesions. MoleMate and SIMSYS rapidly provide accurate images of the pigment, blood, and collagen up to 2mm below the skin to assist in the assessment of moles and lesions. This proven skin cancer related device is used for early diagnoses on various skin histology which includes Basal Cell Carcinoma, Squamous Cell, Hemangioma and the most deadly, Melanoma. MoleMate and SIMSYS are FDA, Health Canada and CE Mark approved. For a complete profile of MedX Health Corp. and its products visit www.medxhealth.com.

This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.